AbbVie received FDA approval for Juvmo (tavapadon) for Parkinson's disease, marking a significant new product launch. An analyst projects Juvmo could become a billion-dollar drug, contributing substantially to AbbVie's long-term growth in its Parkinson's franchise.
AbbVie's new Parkinson's drug, Juvmo, received FDA approval, a major milestone for the company. This approval is significant as it's the first dopaminergic breakthrough for Parkinson's in decades, positioning Juvmo as a key long-term growth driver for AbbVie's Parkinson's franchise. While initial sales are projected to be modest due to gradual insurance coverage build-up, particularly with Medicare, analysts anticipate Juvmo could reach $1.4 billion in sales by 2040 and contribute to a $5 billion peak sales portfolio for AbbVie. This presents a long-term opportunity for ABBV investors, though short-term revenue impact will be limited by the phased rollout and insurance access.